Esperion Therapeutics | ESPR - Assets

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $364.02M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Alterity Therapeutics Limited AUD 27.32M 6.07M Jun/2023
Amarin USD 659.81M 10.31M Sep/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Cipla INR 401.64B 27.77B Sep/2025
CSL USD 39.4B 957M Jun/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Geron USD 567.38M 12.18M Sep/2025
Grifols EUR 23.29B 3.35M Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Heron Therapeutics USD 248.95M 16.86M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 28.09M 2.33M Sep/2025
Moderna USD 12.14B 125M Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
United Therapeutics USD 7.35B 556.9M Sep/2025
Vanda Pharmaceuticals USD 601.14M 23.61M Sep/2025